Literature DB >> 14755775

Liver transplantation for hepatocellular carcinoma: the MELD impact.

Pratima Sharma1, Vijayan Balan, Jose L Hernandez, Ann M Harper, Erick B Edwards, Hector Rodriguez-Luna, Thomas Byrne, Hugo E Vargas, David Mulligan, Jorge Rakela, Russell H Wiesner.   

Abstract

The new allocation policy of the United Network of Organ Sharing (UNOS) based on the model for end-stage liver disease (MELD) gives candidates with stage T1 or stage T2 hepatocellular carcinoma (HCC) a priority MELD score beyond their degree of hepatic decompensation. The aim of this study was to determine the impact of the new allocation policy on HCC candidates before and after the institution of MELD. The UNOS database was reviewed for all HCC candidates listed between July 1999 and July 2002. The candidates were grouped by two time periods, based on the date of implementation of new allocation policy of February 27, 2002. Pre-MELD candidates were listed for deceased donor liver transplantation (DDLT) before February 27,2002, and post-MELD candidates were listed after February 27, 2002. Candidates were compared by incidence of DDLT, time to DDLT, and dropout rate from the waiting list because of clinical deterioration or death, and survival while waiting and after DDLT. Incidence rates calculated for pre-MELD and post-MELD periods were expressed in person years. During the study, 2,074 HCC candidates were listed for DDLT in the UNOS database. The DDLT incidence rate was 0.439 transplant/person years pre-MELD and 1.454 transplant/person years post-MELD (P < 0.001). The time to DDLT was 2.28 years pre-MELD and 0.69 years post-MELD (P < 0.001). The 5-month dropout rate was 16.5% pre-MELD and 8.5% post-MELD (P < 0.001). The 5-month waiting-list survival was 90.3% pre-MELD and 95.7% post-MELD (P < 0.001). The 5-month survival after DDLT was similar for both time periods. The new allocation policy has led to an increased incidence rate of DDLT in HCC candidates. Furthermore, the 5-month dropout rate has decreased significantly. In addition, 5-month survival while waiting has increased in the post-MELD period. Thus, the new MELD-based allocation policy has benefited HCC candidates.

Entities:  

Mesh:

Year:  2004        PMID: 14755775     DOI: 10.1002/lt.20012

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  50 in total

1.  Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.

Authors:  Pratima Sharma; Kathy Welch; Hero Hussain; Shawn J Pelletier; Robert J Fontana; Jorge Marrero; Robert M Merion
Journal:  Dig Dis Sci       Date:  2011-09-28       Impact factor: 3.199

2.  Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists.

Authors:  Pratima Sharma; Sameer D Saini; Latoya B Kuhn; Joel H Rubenstein; Darrell S Pardi; Jorge A Marrero; Philip S Schoenfeld
Journal:  Dig Dis Sci       Date:  2010-10-27       Impact factor: 3.199

3.  Aldoketoreductase family 1B10 (AKR1B10) as a biomarker to distinguish hepatocellular carcinoma from benign liver lesions.

Authors:  Kristina A Matkowskyj; Han Bai; Jie Liao; Wanying Zhang; Haonan Li; Sambasiva Rao; Reed Omary; Guang-Yu Yang
Journal:  Hum Pathol       Date:  2013-12-18       Impact factor: 3.466

Review 4.  Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation.

Authors:  Marta Guerrero-Misas; Manuel Rodríguez-Perálvarez; Manuel De la Mata
Journal:  World J Hepatol       Date:  2015-04-08

5.  Inappropriate inferences from registry data: Pitfalls of inaccurate data handling?

Authors:  Rahul Kakodkar
Journal:  Indian J Gastroenterol       Date:  2017-03-30

6.  Who should undergo liver transplantation for hepatocellular carcinoma? Ablate, wait … and see!

Authors:  Willscott E Naugler; Barry Schlansky; Susan L Orloff
Journal:  Hepat Oncol       Date:  2014-03-20

Review 7.  Multidisciplinary Approach to HCC Management: How Can This Be Done?

Authors:  Melissa M Gadsden; David E Kaplan
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

8.  Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA.

Authors:  John P Duffy; Andrew Vardanian; Elizabeth Benjamin; Melissa Watson; Douglas G Farmer; Rafik M Ghobrial; Gerald Lipshutz; Hasan Yersiz; David S K Lu; Charles Lassman; Myron J Tong; Jonathan R Hiatt; Ronald W Busuttil
Journal:  Ann Surg       Date:  2007-09       Impact factor: 12.969

9.  Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas.

Authors:  Eric C Ehman; Spencer C Behr; Sarah E Umetsu; Nicholas Fidelman; Ben M Yeh; Linda D Ferrell; Thomas A Hope
Journal:  Abdom Radiol (NY)       Date:  2016-05

10.  Inclusion of tumor markers improves the correlation of the Milan criteria with vascular invasion and tumor cell differentiation in patients with hepatocellular carcinoma undergoing liver resection (#JGSU-D-07-00462).

Authors:  Kiyoshi Hasegawa; Hiroshi Imamura; Masayoshi Ijichi; Yutaka Matsuyama; Keiji Sano; Yasuhiko Sugawara; Norihiro Kokudo; Masatoshi Makuuchi
Journal:  J Gastrointest Surg       Date:  2008-01-18       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.